Among the more aggressive EC subtypes, 86% of the grade 3 endometrioid tumors, 95% of serous lesions, 88% of carcinosarcomas, 89% of clear cell, and 77% of undifferentiated were ERBB2-positive (≥1+). This evidence concerns the gene ERBB2 and endometrioid tumor.